antibody

KNG1 (heavy chain, Cleaved-Lys380) Antibody

MBS853889

0.1 mg

215 USD

polyclonal

rabbit

nonconjugated

western blot, ELISA, enzyme immunoassay

Antibody

KNG1 (heavy chain, Cleaved-Lys380) Antibody

KNG1

Alpha-2-thiol proteinase inhibitor; BDK; Bradykinin; Fitzgerald factor; High molecular weight kininogen; HMWK; Ile-Ser-Bradykinin; Kallidin I; Kallidin II; kininogen 1; Kininogen-1; Kininogen-1 heavy chain; Kininogen-1 light chain; KNG; KNG1; Low molecular weight growth-promoting factor; Lysyl-bradykinin; T-kinin; Williams-Fitzgerald-Flaujeac factor

kininogen-1 isoform 2; Kininogen-1; kininogen-1; HMWK; bradykinin; fitzgerald factor; high molecular weight kininogen; alpha-2-thiol proteinase inhibitor; williams-Fitzgerald-Flaujeac factor; kininogen 1; Alpha-2-thiol proteinase inhibitor; Fitzgerald factor; High molecular weight kininogen; HMWK; Williams-Fitzgerald-Flaujeac factorCleaved into the following 6 chains:Kininogen-1 heavy chain; T-kininAlternative name(s):Ile-Ser-Bradykinin

KNG1

KNG1; KNG1; BK; BDK; KNG; BDK; KNG; HMWK

KNG1_HUMAN

Rabbit

Human

427

KNG1 (heavy chain, Cleaved-Lys380) antibody detects endogenous levels of fragment of activated KNG1 resulting from cleavage adjacent to Lys380.

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

100ug/100ul

Store at -20 degree C for 1 year

Western Blot (WB), ELISA (EIA)

WB: 1:500~1:1000, ELISA: 1:10000

Immunogen: The antiserum was produced against synthesized peptide derived from human KNG1. All Sites: Human:Lys380. Pathway: Cleaved-specific

Cancer; Cardiovascular; Cell Biology; Epigenetics & Nuclear Signaling; Developmental Biologys; Immunology; Drug Discovery Products; Metabolism; Neuroscience; Signal Transduction; Stem Cells; Autophagy antibody

Ohkubo I., Biochemistry 23:5691-5697(1984) [PubMed: 6441591]. Takagaki Y., J. Biol. Chem. 260:8601-8609(1985) [PubMed: 2989293]. Ota T., Nat. Genet. 36:40-45(2004) [PubMed: 14702039]. Takagaki Y., J. Biol. Chem. 260:8601-8609(1985) [PubMed: 2989293]. Ota T., Nat. Genet. 36:40-45(2004) [PubMed: 14702039].

4504893

NP_000884.1

NM_000893.3

P01042

43,822 Da

ACE Inhibitor Pathway (198763); Class A/1 (Rhodopsin-like Receptors) Pathway (106357); Complement And Coagulation Cascades Pathway (198880); Complement And Coagulation Cascades Pathway (83073); Complement And Coagulation Cascades Pathway (484); Formation Of Fibrin Clot (Clotting Cascade) Pathway (106057); G Alpha (i) Signalling Events Pathway (119550); G Alpha (q) Signalling Events Pathway (106043); GPCR Downstream Signaling Pathway (119548); GPCR Ligand Binding Pathway (161020)

This gene uses alternative splicing to generate two different proteins- high molecular weight kininogen (HMWK) and low molecular weight kininogen (LMWK). HMWK is essential for blood coagulation and assembly of the kallikrein-kinin system. Also, bradykinin, a peptide causing numerous physiological effects, is released from HMWK. Bradykinin also functions as an antimicrobial peptide with antibacterial and antifungal activity. In contrast to HMWK, LMWK is not involved in blood coagulation. Three transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Nov 2014]

KNG1: (1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin- induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW- kininogen is in contrast to HMW-kininogen not involved in blood clotting. Defects in KNG1 are the cause of high molecular weight kininogen deficiency (HMWK deficiency). HMWK deficiency is an autosomal recessive coagulation defect. Patients with HWMK deficiency do not have a hemorrhagic tendency, but they exhibit abnormal surface-mediated activation of fibrinolysis. 2 isoforms of the human protein are produced by alternative splicing. Protein type: Cell adhesion; Inhibitor; Motility/polarity/chemotaxis; Secreted; Contractile; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 3q27. Cellular Component: extracellular space; plasma membrane; extracellular region. Molecular Function: heparin binding; protein binding; zinc ion binding; cysteine protease inhibitor activity; receptor binding. Biological Process: negative regulation of proteolysis; platelet activation; elevation of cytosolic calcium ion concentration; platelet degranulation; smooth muscle contraction; positive regulation of apoptosis; negative regulation of blood coagulation; negative regulation of cell adhesion; inflammatory response; blood coagulation; blood coagulation, intrinsic pathway; vasodilation. Disease: High Molecular Weight Kininogen Deficiency

0.1 mg

215 USD